Skip Page Header

Home > Dopamine agonists for the treatment of cocaine dependence.

Minozzi, Silvia and Amato, Laura and Pani, Pier Paolo and Solimini, Renata and Vecchi, Simona and De Crescenzo, Franco and Zuccaro, Piergiorgio and Davoli, Marina [The Cochrane Library] . (2015) Dopamine agonists for the treatment of cocaine dependence. London: John Wiley & Sons, Ltd. Cochrane Database of Systematic Reviews (5) DOI: 10.1002/14651858.CD003352.pub4

URL: http://onlinelibrary.wiley.com/enhanced/doi/10.100...

Key results:
We included 24 studies with 2147 participants, who were all addicted to cocaine. Most were men (82.%)with an average age of 37 years. The mean duration of the included trials was seven weeks (range 1.5 to 16 weeks) Twenty-two studies were conducted in USA, one in Brazil and one in Spain; all but four were outpatients.

The included trials studied the following drugs: amantadine, bromocriptine, L dopa/Carbidopa, pergolide, cabergoline hydergine, and pramipexole. All compared dopamine agonist versus placebo. Four studies compared amantidine versus antidepressants.

No differences were found between the drugs and placebo for any of the outcomes considered: dropout (moderate quality of evidence), abstinence (low quality of evidence), severity of dependence (low quality of evidence), adverse events (moderate quality of evidence). Antidepressants was found to be better than the dopamine agonist amantidine for abstinence, but this was based on two studies with very few participants and low quality of evidence. There is no current evidence supporting the clinical use of dopamine agonist medications in the treatment of cocaine misuse. The evidence is current to 12 January 2015.


Item Type
Evidence resource
Publication Type
Review
Drug Type
Cocaine
Intervention Type
AOD disorder drug therapy, AOD disorder treatment method
Date
May 2015
Publisher
John Wiley & Sons, Ltd
Place of Publication
London
Number
5
EndNote

Repository Staff Only: item control page